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pre and IMRT-post plans. Normal tissue complication 
probabilities (NTCPs) for severe proctitis/necrosis/fistula 
were computed applying the Lyman-Kutcher-Burman model 
with Emami parameters (n = 0.02, m = 0.15, D50 = 80 Gy) on 
the rectum DVHs. A paired-sample one-sided Wilcoxon signed 
rank test was used to test for significant (p<0.01) 
differences. 
Results: Median implanted hydrogel volume was 10.6 cc 
[range: 8.3-20.4 cc]. Median V40Gy and V75Gy was 53.75% and 
3.96% for IMRT-pre, and 48.73% and 0.37% for IMRT-post, 
respectively. IMRT-post plans showed significant lower 
predicted Gr2-3 acute and late rectal toxicity rates relative 
to IMRT-pre plans: an absolute median decrease of 3% for 
Gr2-3 acute GI toxicity (p<0.001), a relative decrease of 50% 
for Gr2-3 LRB (p<0.0001) and a mean decrease of 1% for Gr 2-
3 FI (p<0.01). A median absolute reduction of 3.6% (>50% 
relative reduction) (p<0.00001) was predicted by the rectum 
NTCP model. 
Conclusions: In prostate cancer undergoing IMRT predicted 
Gr2-3 acute and late rectal toxicity rates decrease 
significantly by implantation of a hydrogel rectum spacer. We 
anticipate that the effect would be even larger in the high 
risk group. A follow-up study is mandatory to validate the 
predicted (decrease in) probabilities based on observed 
toxicity rates. 
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Purpose/Objective: The aim of this study was to evaluate 
the feasibility and safety of reirradiation using image-guided 
hypofractionated radiotherapy and real time tracking (4D 
Calypso® System) in patients (pts) with recurrence of 
prostate cancer after external beam radiotherapy (EBRT). 
Materials and Methods: Between May 2013 and August 2014, 
6 pts with local recurrence after EBRT were treated using 
VMAT (Volumetric Modulated Arc Therapya) and 4D localize 
and real time tracking Calypso® System. Houston-Phoenix 
definition (PSA nadir + 2 ng/mL) was used to define 
biochemical failure and all pts were assessed with endorectal 
MRI and choline PET/CT. Patients classification according to 
D’Amico Risk Group Class was the following: 2 pts high, 4 
intermediate and 1 low risk class. Mean time to recurrence 
was 56.4 months (range 19-96 months). All the pts had been 
treated with 3DCRT with a mean dose of 74.4 (72-76, median 
74). Total reirradiation dose was 25 Gy (5 fractions of 500 
cGy on alternate days). Simulation CT with specific 
preparation (empty rectum, filled bladder with catheter 
insertion) was performed after 5-7 days from Calypso® 
beacons implatation. Treatment planning was performed with 
Varian Eclypse v.8.6 in four pts and with v.10.6 in two; two 
pts were treated using X6 FFF (flattening filter free) photons. 
Mean CTV volume was 22.77cc (range 16.56-29.6 cc); PTV 
was obtained with a 3 mm isotropic expansion. Contouring of 
Organ At Risk (OAR) included urethra. Mean PTV dose 
coverage was 25.06 Gy, (range 24.7-25.4 Gy); maximum PTV 
allowed dose was 104% (urethra maximum dose allowed was 
102%). OAR dose constraints were obtained converting the 
RTOG conventional ones using alfa/beta ratio. Mean CI 
(conformity index) was 0.92 (range 0.89-1.05). Radiation 
Therapy Oncology Group/European Organization for Research 
and Treatment of Cancer criteria were used to assess toxicity 
of both treatments. 
Results: After a median follow-up of 14 months (range 2-17.6 
months), all pts were alive with no evidence of urinary or 
rectal toxicity. In four pts a biochemical response was 
observed; one pts, after an initial PSA reduction, showed a 
rising of the marker due to metastatic disease. One patient is 
not yet evaluable. 
Conclusions: Salvage hypofractionated radiotherapy after 
conventional EBRT is feasible with acceptable risk of toxicity 
in pts with relapsed prostate cancer. Initial data suggest 
effectivness of this approach but a longer follow up and a 
larger number of pts are needed to confirm it. 
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Purpose/Objective: A number of studies have been 
published, which predict the probability of acute and late 
toxicity after radiotherapy (RT) for prostate cancer (Pca), but 
no user-friendly tool is available to help radiation oncologists 
applying the results coming from these studies. Aim of this 
work was therefore to design and build a web application 
which can support radiation oncologists in treatment planning 
and evaluation, by computing the probabilities of various 
acute and long term toxicities, as a function of dose 
distribution to organs at risk and patient's characteristics. 
Materials and Methods: 4 published studies devoted to 
prediction of acute and late GI toxicity after RT for Pca and 
presenting predictive models based on logistic regression 
were considered. Current web and database technologies 
were used to develop the web tool by means of open source 
software (HTML, PHP, Javascript, MySQL). 11 models (5 for 
acute and 6 for late toxicity) have been configured into the 
system and new models could possibly be added in the 
future. Model and variable names, with their regression 
coefficients and their standard errors when available, are 
stored in a database and used to compute in real-time the 
probabilities of the different endpoints. We chose to insert a 
free registration procedure before use of the web tool is 
allowed, in order to have a check on people accessing it. The 
web application can be used by any of the most common 
browsers (Chrome, Mozilla Firefox, Internet Explorer). 
Results: The user can chose between models including the 
actual dose distribution in the patient, if a RT plan is already 
available, or models giving probabilities for different 
standard dose-volume levels. Probability uncertainties are 
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also computed and reported as confidence intervals in the 
outcome reports. 
Relevant literature was inserted and made readily available 
to the user. 
Figure 1 shows a screen shot of the web tool:  
 
Conclusions: This work proved that it is possible to provide 
clinicians with a support tool that enables them to use in 
their clinical practice results coming from scientific 
literature, thus helping translation of clinical studies into 
daily routine. 
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Purpose/Objective: Globally, prostate cancer is responsible 
for around 250000 deaths annually. Radiotherapy is an 
effective definitive treatment and, for more aggressive 
disease, is commonly preceded by neo-adjuvant androgen 
deprivation therapy (ADT). It has been demonstrated that 
dose escalated radiotherapy improves biochemical free 
survival but not overall survival. Further dose escalation is 
limited by OAR tolerances. Giving a further focal boost to the 
dominant intra-prostatic lesion (DIPL) appears to be feasible. 
The DIPL is effectively identified using multi-parametric (MP) 
MR imaging, however, ADT results in a reduction in prostate 
and tumour volume and also a loss of contrast on T2w MR 
images, making lesions less conspicuous. The DIPL is 
therefore conventionally identified on pre-hormone imaging 
but it is known that response to therapy is variable and 
directing a DIPL boost to disease that is resistant to ADT may 
be most likely to improve clinical outcome. The aim of this 
work was to compare pre and post treatment imaging to 
evaluate the feasibility of using post treatment MP-MRI to 
locate the DIPL. 
Materials and Methods: Six patients with prostate cancer 
stage T2b or greater were recruited. All underwent local pre 
ADT DWI. Patients were imaged post ADT at 1.5 T (Achieva, 
Philips Medical Systems, Best, The Netherlands) using the 
cardiac coil. The MR examination included high resolution 
T2w images, DCE-MRI and diffusion-weighted imaging (DWI). 
ADC and DCE-MRI parameter maps were calculated on a 
voxel-by-voxel basis for the whole prostate. 
Results: Four patients had a clear DIPL pre ADT. This 
remained largely unchanged in appearance in three cases 
post ADT, as shown in the example case in the top row of 
figure 1, where arrows indicate the high flow (left, Fp in 
ml/ml tissue/min overlayed on T2w imaging), low ADC (right, 
overlayed on T2w imaging) regions matching those reported 
as tumour on pre-treatment imaging. In one case the pre ADT 
DIPL in the right peripheral zone was hard to identify post 
ADT on T2w imaging (black arrow bottom row, figure 1). 
However a further lesion in the left anterior gland (white 
arrow), which was equivocal in appearance pre-treatment, 
was now conspicuous in both Fp (left) and ADC maps (right). 
 
 
 
Conclusions: This study has shown that for this cohort post 
ADT MP-MR is effective at identifying a DIPL for focal boost 
therapy. In one case the area which would be targeted for 
dose escalation changed pre and post ADT. The use of post 
ADT Fp and ADC therefore appears to have potential for 
identifying areas of disease which are resistant to ADT. It is 
known from animal studies that these areas are likely to be 
radio-resistant and benefit most from dose escalation. Using 
pre-ADT MP-MR may therefore carry the risk of failing to 
correctly identify the area of prostate requiring dose 
escalation. This study forms part of a larger piece of work 
aiming to validate these findings and assess changes in 
tumour MP-MR characteristics during radiotherapy after neo-
adjuvant ADT. 
 
 
 
 
